CD19 and plasma cell myeloma: Nonetheless, in preclinical trials CD19-specific CAR T cells have demonstrated pronounced activity versus CD19-positive subclones of myeloma cells, both in the mono-specific format and as parts of tandem constructs jointly with anti-BCMA CARs [187,188].